[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639117":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":24,"centralContacts":29,"locations":39,"responsibleParty":59,"collaborators":7,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":7,"enrollmentInfo":73,"targetDuration":7,"studyType":76,"phases":7,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":42,"whyStopped":7,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Istituto Oncologico Veneto IRCCS","OTHER",null,[9,13,17,21],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"PROCEDURE","Upfront Breast Surgery","Upfront Conservative or Demolitive Breast Surgery",{"type":14,"name":15,"description":16,"armGroupLabels":7,"otherNames":7},"RADIATION","Adjuvant Radiotherapy","Adjuvant Breast or Chest Wall Radiotherapy after Breast Surgery",{"type":18,"name":19,"description":20,"armGroupLabels":7,"otherNames":7},"DRUG","Endocrine Therapy","Adjuvant or Neoadjuvant Endocrine Therapy",{"type":18,"name":22,"description":23,"armGroupLabels":7,"otherNames":7},"Chemotherapy","Adjuvant or Neoadjuvant Chemotherapy",[25],{"name":26,"affiliation":27,"role":28},"Francesco Milardi, MD","Veneto Institute of Oncology IRCCS","STUDY_CHAIR",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":7,"email":34},"Massimo Ferrucci, MD PhD","CONTACT","049 821 5500","massimoferrucci@gmail.com",{"name":36,"role":32,"phone":37,"phoneExt":7,"email":38},"Daniele Passeri, MD","+39 333 383 9397","daniele.passeri.1995@gmail.com",[40],{"facility":41,"status":42,"city":43,"state":7,"zip":7,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Veneto Institute of Oncology","RECRUITING","Padova","Italy","IT",{"type":47,"coordinates":48},"Point",[49,50],11.14261,44.38225,{"lat":50,"lon":49},[53,54,56],{"name":31,"role":32,"phone":33,"phoneExt":7,"email":34},{"name":36,"role":32,"phone":55,"phoneExt":7,"email":38},"+393333839397",{"name":57,"role":58,"phone":7,"phoneExt":7,"email":7},"Francesco Milardi","SUB_INVESTIGATOR",{"type":60,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Ferrucci Massimo","MD PhD","100639117","negative-hormone-receptor-and-apocrine-lobular-invasive-breast-cancer-100639117",false,"NCT07613151","Negative Hormone Receptor and APOcrine Lobular Invasive Breast Cancer","NAPOLI Study: Negative Hormone Receptor and APOcrine Lobular Invasive Breast Cancer - A Retrospective Multicenter Observational Study","NAPOLI","Inclusion Criteria:\n\n* Female or male patients aged ≥18 years.\n* Histologically confirmed invasive lobular carcinoma of the breast.\n* Presence of apocrine differentiation\u002Ffeatures documented in pathology report or confirmed by local pathology review.\n* Negative hormone receptors.\n* Diagnosis and\u002For treatment at one of the participating centers.\n* Availability of essential clinicopathological data.\n* Availability of follow-up data, when applicable.\n\nExclusion Criteria:\n\n* Pure ductal carcinoma without lobular invasive component.\n* Metastatic tumor to the breast from non-breast primary cancer.\n* Insufficient pathological documentation to confirm eligibility.\n* Missing essential clinical data.\n* Patients who denied consent for retrospective data use, where applicable by local regulations.","ALL","18 Years",{"count":74,"type":75},250,"ESTIMATED","OBSERVATIONAL","The NAPOLI Study is a retrospective multicenter observational study designed to characterize negative hormone receptor and apocrine lobular invasive breast cancer. The study will collect real-world clinicopathological, molecular, therapeutic and outcome data from patients diagnosed and treated at participating centers. The aim is to describe the clinical behavior, pathological features, receptor profile, treatments received and oncologic outcomes of this rare breast cancer subtype.",[79],"Lobular Breast Carcinoma",[81,82,83],"Breast","Cancer","Lobular Neoplasia","2026-05-23",{"date":86,"type":87},"2026-05-29","ACTUAL",{"date":89,"type":87},"2026-05-01",{"date":91,"type":75},"2027-12-31",{"name":5,"class":6},1]